Scalper1 News
Big-cap biotech Biogen (BIIB) was down 3% in afternoon trading Friday as its R&D head departed, and Cowen issued a cautious note about upcoming Alzheimer’s disease data. Biogen said Douglas Williams is leaving at the end of July to head a biotech startup “with potential in cancer diagnostics and therapy.” Chief Medical Officer Alfred Sandrock and Chief Scientific Officer Spyros Artavanis-Tsakonas will take over his duties. Williams joined Biogen Scalper1 News
Scalper1 News